Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Delivery of renal replacement therapy in the trial

From: Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial

  Intermittent hemodialysis Sustained low-efficiency dialysis Continuous renal replacement therapy
Patient hemodynamic profile Off all vasopressors and inotropes (SOFAcv <2) Receiving any dose of vasopressor or inotrope (SOFAcv ≥2) Receiving any dose of vasopressor or inotrope (SOFAcv ≥2)
Minimum session duration (hrs) 3 8 24
Minimum frequency 3 times/week 3 times/week NA
Blood flow target (mL/min) 200 to 400 200 to 300 100 to 250
Dialysate flow (mL/min) 500 to 800 200 to 400 NA
Total effluent (mL/kg/hr) NA NA ≥25
Anticoagulation options Heparin Heparin Heparin
  None None None
    Regional citrate anticoagulation
Fluid removal rate To be determined by the nephrologist and/or critical care physician
  1. This table outlines guidelines for renal replacement therapy prescription by modality for randomized participants. NA, not applicable; SOFAcv, cardiovascular component of the Sequential Organ Failure Assessment score [22].